{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:11:49Z","timestamp":1793272309198,"version":"4.5.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Basic Research Program of China (973 Program)","doi-asserted-by":"crossref","award":["2019YJ0139"],"award-info":[{"award-number":["2019YJ0139"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1007\/s10792-020-01490-6","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T02:41:42Z","timestamp":1593571302000},"page":"3059-3065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The efficacy and mechanism for action of iguratimod in primary Sj\u00f6gren\u2019s syndrome patients"],"prefix":"10.1007","volume":"40","author":[{"given":"Wei","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingshu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,1]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/art.10221","volume":"46","author":"JP Ioannidis","year":"2002","unstructured":"Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren\u2019s syndrome. Arthritis Rheum 46:741\u2013747","journal-title":"Arthritis Rheum"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1172\/JCI0214121","volume":"109","author":"J Groom","year":"2002","unstructured":"Groom J, Kalled SL, Cutler AH et al (2002) Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren\u2019s syndrome. J Clin Invest 109:59\u201368","journal-title":"J Clin Invest"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.3109\/s10165-012-0724-8","volume":"23","author":"N Ishiguro","year":"2013","unstructured":"Ishiguro N, Yamamoto K, Katayama K et al (2013) Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol 23:430\u2013439","journal-title":"Mod Rheumatol"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00029330-200804010-00008","volume":"121","author":"LJ Lu","year":"2008","unstructured":"Lu LJ, Teng JL, Bao CD et al (2008) Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl) 121:615\u2013619","journal-title":"Chin Med J (Engl)"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/s10165-006-0542-y","volume":"17","author":"M Hara","year":"2007","unstructured":"Hara M, Abe T, Sugawara S et al (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17:1\u20139","journal-title":"Mod Rheumatol"},{"key":"1490_CR6","first-page":"169","volume":"20","author":"CK Kim","year":"2007","unstructured":"Kim CK, Sakudo A, Taniuchi Y et al (2007) Late-onset olfactory deficits and mitral cell loss in mice lacking prion protein with ectopic expression of Doppel. Int J Mol Med 20:169\u2013176","journal-title":"Int J Mol Med"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1002\/art.24643","volume":"61","author":"LJ Lu","year":"2009","unstructured":"Lu LJ, Bao CD, Dai M et al (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum 61:979\u2013987","journal-title":"Arthritis Rheum"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0165-5728(98)00056-3","volume":"89","author":"Y Aikawa","year":"1998","unstructured":"Aikawa Y, Tanuma N, Shin T et al (1998) A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 89:35\u201342","journal-title":"J Neuroimmunol"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1248\/bpb1978.15.649","volume":"15","author":"K Tanaka","year":"1992","unstructured":"Tanaka K, Aikawa Y, Kawasaki H et al (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 15:649\u2013655","journal-title":"J Pharmacobiodyn"},{"key":"1490_CR10","doi-asserted-by":"crossref","first-page":"356040","DOI":"10.1155\/2015\/356040","volume":"2015","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zhu Q, Song J et al (2015) Regulatory effect of Iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm 2015:356040","journal-title":"Mediat Inflamm"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/rheumatology\/keg381","volume":"42","author":"K Tanaka","year":"2003","unstructured":"Tanaka K, Yamamoto T, Aikawa Y et al (2003) Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 42:1365\u20131371","journal-title":"Rheumatology (Oxford)"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"e108273","DOI":"10.1371\/journal.pone.0108273","volume":"9","author":"Q Yan","year":"2014","unstructured":"Yan Q, Du F, Huang X et al (2014) Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL\/lpr mice. PLoS ONE 9:e108273","journal-title":"PLoS ONE"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren\u2019s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10792-017-0577-4","volume":"38","author":"YS Kang","year":"2018","unstructured":"Kang YS, Lee HS, Li Y et al (2018) Manifestation of meibomian gland dysfunction in patients with Sjogren\u2019s syndrome, non-Sjogen\u2019s dry eye, and non-dry eye controls. Int Ophthalmol 38:161\u20131167","journal-title":"Int Ophthalmol"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/14397595.2015.1069475","volume":"26","author":"Y Yoshioka","year":"2016","unstructured":"Yoshioka Y, Takahashi N, Kaneko A et al (2016) Disease activity early in treatment as a predictor of future low disease activity in RA patients treated with iguratimod. Mod Rheumatol 26:169\u2013174","journal-title":"Mod Rheumatol"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s10067-015-2999-6","volume":"34","author":"XW Duan","year":"2015","unstructured":"Duan XW, Zhang XL, Mao SY et al (2015) Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial. Clin Rheumatol 34:1513\u20131519","journal-title":"Clin Rheumatol"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10792-016-0321-5","volume":"37","author":"T Nagashima","year":"2017","unstructured":"Nagashima T, Ishihara M, Shibuya E et al (2017) Three cases of tubulointerstitial nephritis and uveitis syndrome with different clinical manifestation. Int Ophthalmol 37:753\u2013759","journal-title":"Int Ophthalmol"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-020-01490-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-020-01490-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T23:28:00Z","timestamp":1723159680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-020-01490-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s10792-020-01490-6","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]},"assertion":[{"value":"12 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that no competing conflict of interests and non-financial conflict of interests or non-commercial interests in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research has been approved by the Ethic Committee of The West China Hospital, Sichuan University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all patients before they participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}